Skip to main content
TipRanks
Go Ultimate75% OFF

NexgenRx (NXG) Financial Statements

19 Followers

NexgenRx Financial Overview

NexgenRx's market cap is currently $50.49M. The company's EPS TTM is ―; its P/E ratio is 21.32; and it has a dividend yield of 2.82%. NexgenRx has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue―――――
Gross Profit$ 10.82M―$ 9.81M$ 9.67M$ 8.37M
Operating Income$ -143.88K―$ 2.20M$ 2.16M$ 93.52K
EBITDA$ 1.15M―$ 3.40M$ 2.96M$ 815.97K
Net Income$ -331.97K―$ 4.02M$ 2.12M$ -207.94K
Balance Sheet
Cash & Short-Term Investments―――――
Total Assets$ 30.20M$ 25.75M$ 29.44M$ 25.24M$ 21.19M
Total Debt$ 461.88K$ 432.47K$ 401.76K$ 1.45M$ 4.10M
Net Debt$ -1.41M$ -1.33M$ -1.92M$ 643.66K$ 3.57M
Total Liabilities$ 22.48M$ 16.90M$ 19.72M$ 19.72M$ 19.35M
Stockholders' Equity―――――
Cash Flow
Free Cash Flow$ 1.03M―$ 2.45M$ 2.65M$ 1.05M
Operating Cash Flow―――――
Investing Cash Flow―――――
Financing Cash Flow―――――

Currency in USD

NexgenRx Earnings and Revenue History

01.5M3M4.5M0 %0.4 %0.8 %1.2 %EarningsProfit Margin2021RevenueEarningsProfit Margin

NexgenRx Liabilities to Assets

012M24M36M66 %67 %68 %69 %LiabilitiesLiabilities to Assets2021AssetsLiabilitiesLiabilities to Assets

NexgenRx Cash Flow

00.30.50.811.32021OperatingInvestingFinancing

NexgenRx Forecast EPS vs Actual EPS

00000Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26EPS EstimateBeatMiss